Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The provided label excerpts support the requested suicidality/monitoring claim, but the supplied AI response includes numerous additional assertions (e.g., indications, tablet/imprint details, side effects, patent/generics/manufacturers) that are not supported by the included FDA label excerpts and cannot be verified against the supplied prescribing information.
Category Scores
Accurate Statements
The FDA label for Escitalopram Oral Solution indicates an increased risk of suicidal thoughts and behaviors in certain age groups (patients age 24 years and younger; pediatric patients) and recommends monitoring and counseling.
Supported by Label 5.1 (suicidal thoughts/behaviors incidence greater than placebo in antidepressant-treated patients age 24 years and younger; monitoring and consider regimen change) and reinforced by 8.4 (increased risk in pediatric patients) and 17 (advise patients/families/caregivers to look for suicidal ideation/behavior and report, especially during treatment and dose adjustments).
Unsupported Statements
Escitalopram is prescribed to treat depression.
Not supported by the supplied label excerpts (only suicidality/monitoring sections were provided).
Escitalopram is prescribed to treat generalized anxiety disorder.
Not supported by the supplied label excerpts.
Escitalopram is available in tablet form.
Not supported by the supplied label excerpts.
Escitalopram is available in oral solution form.
The label excerpt provided is for oral solution, but availability in form(s) beyond what is shown in the excerpt is not explicitly supported in the included text. (Partial/indeterminate from provided excerpts.)
Escitalopram tablets are typically white and film-coated.
Not supported by the supplied label excerpts.
Escitalopram tablets are usually imprinted with the strength of the dosage; 10 mg tablets may be imprinted with "TLD" and "10"; 20 mg tablets may be imprinted with "TLD" and "20"; imprints can vary by manufacturer.
Not supported by the supplied label excerpts.
Escitalopram is commonly available in 5 mg, 10 mg, and 20 mg tablet strengths.
Not supported by the supplied label excerpts.
The oral solution of escitalopram is typically available in a concentration of 1 mg/mL.
Not supported by the supplied label excerpts.
Escitalopram works by increasing the amount of serotonin.
Not supported by the supplied label excerpts.
Escitalopram is prescribed for the treatment of major depressive disorder in adults.
Not supported by the supplied label excerpts.
Escitalopram is prescribed for the treatment of major depressive disorder in adolescents 12 years of age and older.
Not supported by the supplied label excerpts.
Escitalopram is prescribed for the treatment of generalized anxiety disorder in adults.
Not supported by the supplied label excerpts.
Common side effects associated with escitalopram use include nausea/insomnia/ejaculation disorder/fatigue/increased sweating.
Not supported by the supplied label excerpts.
The patent for escitalopram (originally marketed as Lexapro) has expired; generic production/sale is enabled; multiple companies manufacture including Teva, Mylan, Aurobindo.
Not supported by the supplied label excerpts.
Escitalopram is the S-enantiomer of citalopram.
Not supported by the supplied label excerpts.
Escitalopram is generally considered to have a similar efficacy profile to other SSRIs; may have a different side effect profile or potency compared with other SSRIs.
Not supported by the supplied label excerpts.
Escitalopram can interact with certain drugs.
Not supported by the supplied label excerpts.
Patients should take escitalopram exactly as prescribed.
Not supported by the supplied label excerpts (only suicidality monitoring/counseling were provided).
Stopping escitalopram suddenly can lead to withdrawal symptoms.
Not supported by the supplied label excerpts.
Pregnant or breastfeeding individuals should consult their healthcare provider regarding escitalopram.
Not supported by the supplied label excerpts.
Lexapro is the brand name under which escitalopram was originally marketed.
Not supported by the supplied label excerpts.
Escitalopram is the generic name of the active pharmaceutical ingredient.
Not supported by the supplied label excerpts.
Contradictions
Important Omissions
For the safety claim, the AI response does not quote or explicitly include the label’s specific counseling/monitoring instructions verbatim beyond the high-level statement (though it is generally consistent).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The core suicidality/monitoring claim is supported, but many other assertions are unsupported by the provided label excerpts, which could mislead users if treated as label-verified. Since the task is label alignment, the main risk is misinformation rather than direct contradiction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most statements in the AI response are not supported by the supplied FDA label excerpts (only suicidality-related sections were provided).
Suggested Improvement
Limit output to claims explicitly supported by the provided label text (5.1, 8.4, 17) or provide the additional relevant label sections before making other claims (indications, dosing, formulation/imprints, side effects, drug interactions, pregnancy/breastfeeding, etc.).